Walleye Capital LLC Mersana Therapeutics, Inc. Transaction History

Walleye Capital LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.06 - $3.91 $1.98 Million - $7.3 Million	1,866,568 Added 1205.02%	2,021,467 $2.57 Million
Q2 2023 Aug 14, 2023	SELL	$3.08 - $9.55 $210,946 - $654,069	-68,489 Reduced 30.66%	154,899 $509,000
Q1 2023 May 15, 2023	BUY	$4.0 - $7.02 $893,552 - $1.57 Million	223,388 New	223,388 $918,000
Q2 2022 Aug 08, 2022	SELL	$2.84 - $5.0 $1.09 Million - $1.92 Million	-383,986 Reduced 97.4%	10,264 $47,000
Q1 2022 May 16, 2022	SELL	$3.74 - $6.63 $1,907 - $3,381	-510 Reduced 0.13%	394,250 $1.57 Million
Q4 2021 Mar 03, 2022	BUY	$5.48 - $9.86 $1.51 Million - $2.72 Million	275,458 Added 230.89%	394,760 $2.46 Million
Q3 2021 Nov 15, 2021	BUY	$8.56 - $14.47 $688,968 - $1.16 Million	80,487 Added 207.36%	119,302 $1.13 Million
Q2 2021 Aug 16, 2021	BUY	$13.28 - $18.07 $515,463 - $701,387	38,815 New	38,815 $527,000
Q4 2019 Feb 14, 2020	SELL	$1.45 - $6.73 $20,665 - $95,915	-14,252 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$1.54 - $4.2 $383 - $1,045	249 Added 1.78%	14,252 $23,000
Q2 2019 Aug 14, 2019	BUY	$3.84 - $6.4 $53,771 - $89,619	14,003 New	14,003 $57,000

125

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $52.5M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.